CRMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRMT is not a good buy right now for a Beginner long-term investor with $50,000-$100,000. The stock is showing a mild short-term bounce, but the broader trend is still weak and the latest analyst action cut the price target sharply to $14 while keeping a Hold rating. With no strong proprietary buy signal, no recent news catalyst, and no clear financial snapshot showing improved fundamentals, this is better treated as a hold rather than an immediate buy.
The technical picture is mixed to bearish. MACD histogram is slightly positive and expanding, which supports short-term momentum improvement, but RSI at 54.96 is neutral and does not indicate strong upside momentum. More importantly, the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, which signals the longer-term trend remains under pressure. Price at 12.12 is sitting near the pivot of 12.05, with resistance at 12.96 and 13.53 and support at 11.14 and 10.57. The current setup suggests a limited near-term upside unless the stock can reclaim resistance levels decisively.
Hedge funds are reported buying aggressively, with buying up 14186.49% over the last quarter. MACD is positive and expanding, suggesting improving short-term momentum. The stock trend model shows a modest chance of gains over the next day, week, and month. Price is holding close to the pivot level, which can support a short-term rebound if momentum continues.
Jefferies cut the price target to $14 from $29 and maintained only a Hold rating, citing funding constraints, weather-related distortions, and macro pressure in the subprime lending environment. There was no news in the past week, so there is no fresh catalyst supporting a stronger move. Insiders are neutral, and the technical trend remains bearish on the moving averages. No AI Stock Picker or SwingMax signal is present today.
No latest quarter financial snapshot was provided, so there is not enough data to assess recent revenue, earnings, or margin growth trends. Because the financial snapshot is missing, there is no evidence here of an improving latest quarter season to justify a strong long-term buy decision.
Recent analyst sentiment has turned more cautious. Jefferies lowered its price target from $29 to $14 and kept a Hold rating, reflecting concerns about funding constraints, weather impacts, and macro pressure in the subprime market. Wall Street’s view appears mixed but tilted cautious: the pros are that hedge funds are accumulating shares and there may be upside if operational constraints ease, while the cons are the reduced target, Hold rating, and lack of clear fundamental or news-driven momentum.
